diffuse large B-cell lymphoma
Conditions
Interventions
case series:PLD 25 mg/ m2,iv,d1,cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2, up to 2 mg, or vindesine 3 mg/m2, intravenously (iv.) all on day 1
and prednisone 100 mg orally on days 1 to 5, with or without rituximab 375 mg/m2, iv. on day 0, administered every 21 days (n=304) for six or eight cycle
Sponsors
Beijing Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: The enrolled patients were histopathologically definitively diagnosed with DLBCL, aged 60 or older, or aged 18-60 with arrhythmia, coronary heart disease, abnormal heart function (identified by the New York Heart Association [NYHA] as Grade I), or hypertension but well controlled. Other inclusion criteria included objectively measurable tumor lesions, ECOG score = 2 points, expected survival > 3 months, normal blood, liver and kidney function, and LVEF = 50%.
Exclusion criteria
Exclusion criteria: 1) Patients with grade II or higher heart disease identified based on the NYHA score; 2) Invasion of the central nervous system; 3) Other malignancies in the past 5 years, except cervical carcinoma in situ or non-malignant melanoma skin cancer; 4) Pregnancy or breastfeeding women and patients of childbearing age who refuse to adopt appropriate contraceptive measures during treatment; 5) Participating in other clinical researches at the same time.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression?Free?Survival;Cardiac toxicity;the incidence of adverse events; | — |
Countries
China
Contacts
Public ContactZhu Jun
Beijing Cancer Hospital
Outcome results
None listed